Diabetic Foot Ulcers

Diabetic foot ulcers (DFUs) affect approximately 1.4 to 2 million individuals in the United States annually, often resulting from insufficient blood flow that impedes healing. Zhittya Genesis Medicine is developing a treatment utilizing human Fibroblast Growth Factor 1 (FGF-1) to promote therapeutic angiogenesis—the formation of new blood vessels—to enhance blood supply and facilitate healing in affected areas. Previous Phase II clinical trials have demonstrated that FGF-1 can significantly accelerate the healing of DFUs, with some studies reporting complete healing in all treated ulcers without adverse events. Recognizing the substantial unmet medical need, Zhittya aims to advance this innovative therapy through clinical development, potentially qualifying for the U.S. FDA's "Medical Breakthrough Therapy" designation. Read more in our white paper below: